IMGT Corporation Limited
IMGT, founded in 2010 and KONEX-listed in 2023, develops the IMD10 focused ultrasound system for anticancer drug delivery.
As of 2026-10-10, IMGT Corporation Limited has 1 MFDS Innovative Medical Device designation, 1 Korean MFDS device approval, 25 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2010 and listed on KONEX in 2023, IMGT is a medical device company specializing in therapeutic focused ultrasound. It developed the IMD10 focused ultrasound system for anticancer drug delivery, enabling ChemoSono Therapy that enhances drug penetration into tumor tissue. It completed the world's first ChemoSono Therapy clinical trial in pancreatic cancer patients at Seoul National University Hospital, received FDA Breakthrough Device Designation for IMD10 in February 2025, and obtained FDA IDE approval for a US pivotal clinical trial in November 2025.
Regulatory approvals
data.go.kr1 Innovative Medical Device designations · 2026 / 1 Korean MFDS device approvals · 2026
- InnovativeIMD102026-01-22Innovative Medical Device designation
- MFDSHigh intensity focused Ultrasonic surgical system2026-08-03Product approval · Class 3제허 26-592 호
Clinical trials
data.go.kr1 MFDS clinical trial authorisations · 2023 (Phase 1 1)
- Phase 1IMP3012023-08-03
2 trial sites
Global clinical trials
ClinicalTrials.gov · sponsor-matchedNot yet recruiting · 2026-09 · NCT07325214
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- Comparison of mechanical and thermal effects of focused ultrasound on drug delivery efficiency and toxicity for pancreatic cancer treatment.
Ultrasonics · 2026-03 · Kim D, Hong J, Kim D 외 6
- Perfluoropentane Phase-Change Nanodroplets for Focused Ultrasound-Enhanced Drug Penetration and Immune Response.
Pharmaceutics · 2026-02 · Shin K, Kim D, Moon H 외 3
- Antitumor Effects of Doxorubicin-Loaded Cellulose Nanoparticles in the Rabbit VX2 Liver Tumor Model.
Cardiovascular and interventional radiology · 2026-01 · Lee J, Kim KY, Lee CH 외 6
- Ultrasound-Sensitive Liposomal Exatecan for Tumor-Specific Drug Release for Treatment of Pancreatic Cancer.
Pharmaceutics · 2025-12 · Kim D, Moon H, Han S 외 1
- Focused ultrasound-triggered doxorubicin liposomes reshape tumor microenvironment to boost checkpoint depletion in triple-negative breast cancer model.
Journal of controlled release : official journal of the Controlled Release Society · 2025-12 · Lee SN, Choi JH, Moon H 외 4
- Tumor suppression effect of ultrasound-sensitive nanoparticles with focused ultrasound in a pancreas cancer xenograft model.
European radiology experimental · 2024-03 · Kim S, Lee JY, Park EJ 외 4
- Optimized treatment parameter by computer simulation for high-intensity focused ultrasound treatment of uterine adenomyosis: Short-term and long-term results.
PloS one · 2024-01 · Bae JS, Lee JY, Chung HH 외 8
- Drug delivery by sonosensitive liposome and microbubble with acoustic-lens attached ultrasound: an in vivo feasibility study in a murine melanoma model.
Scientific reports · 2023-09 · Park JH, Lee BC, Seo YC 외 5
- Development of a Polymersome-Based Nanomedicine for Chemotherapeutic and Sonodynamic Combination Therapy.
International journal of molecular sciences · 2023-01 · Kim M, Kim D, Jang Y 외 5
- Evading Doxorubicin-Induced Systemic Immunosuppression Using Ultrasound-Responsive Liposomes Combined with Focused Ultrasound.
Pharmaceutics · 2022-11 · Lee J, Um W, Moon H 외 6
Show 15 more publications
- Enhanced delivery to brain using sonosensitive liposome and microbubble with focused ultrasound.
Biomaterials advances · 2022-10 · Moon H, Hwang K, Nam KM 외 10
- Effects of Lipid Shape and Interactions on the Conformation, Dynamics, and Curvature of Ultrasound-Responsive Liposomes.
Pharmaceutics · 2022-07 · Lee H, Moon H, Kim HR
- Ultrasound-Responsive Liposomes for Targeted Drug Delivery Combined with Focused Ultrasound.
Pharmaceutics · 2022-06 · Kim YS, Ko MJ, Moon H 외 4
- Ultrasound-triggered imaging and drug delivery using microbubble-self-aggregate complexes.
Journal of biomaterials science. Polymer edition · 2022-01 · Chung IJ, Moon H, Jeon SI 외 2
- Early response evaluation of doxorubicin-nanoparticle-microbubble therapy in orthotopic hepatocellular carcinoma rat model using contrast-enhanced ultrasound and intravoxel incoherent motion-diffusion MRI.
Ultrasonography (Seoul, Korea) · 2022-01 · Yang HK, Kim JH, Lee HJ 외 3
- PMP(Porphyrin-Micelle-PSMA) Nanoparticles for Photoacoustic and Ultrasound Signal Amplification in Mouse Prostate Cancer Xenografts.
Pharmaceutics · 2021-10 · Kim D, Han W, Chang JH 외 1
- Development and evaluation of an ultrasound-triggered microbubble combined transarterial chemoembolization (TACE) formulation on rabbit VX2 liver cancer model.
Theranostics · 2021-01 · Kim D, Lee JH, Moon H 외 10
- PD-L1 Targeting Immune-Microbubble Complex Enhances Therapeutic Index in Murine Colon Cancer Models.
Pharmaceuticals (Basel, Switzerland) · 2020-12 · Kim D, Lee SS, Moon H 외 2
- Combination Therapy with Doxorubicin-Loaded Reduced Albumin Nanoparticles and Focused Ultrasound in Mouse Breast Cancer Xenografts.
Pharmaceuticals (Basel, Switzerland) · 2020-09 · Kim D, Lee SS, Yoo WY 외 6
- Antitumor Efficacy of Focused Ultrasound-MFL Nanoparticles Combination Therapy in Mouse Breast Cancer Xenografts.
Materials (Basel, Switzerland) · 2020-03 · Kim D, Han J, Park SY 외 3
- Combined treatment of sorafenib and doxorubicin-loaded microbubble-albumin nanoparticle complex for hepatocellular carcinoma: A feasibility study.
PloS one · 2020-01 · Lee S, Kim JH, Moon H 외 2
- Evaluation of lymph node metastasis in a rabbit tumor model: correlations between contrast-enhanced ultrasound and pathologic findings.
Ultrasonography (Seoul, Korea) · 2020-01 · Ha SW, Lee HJ, Cho AS 외 2
- Antitumor Effects of Intra-Arterial Delivery of Albumin-Doxorubicin Nanoparticle Conjugated Microbubbles Combined with Ultrasound-Targeted Microbubble Activation on VX2 Rabbit Liver Tumors.
Cancers · 2019-04 · Lee JH, Moon H, Han H 외 6
- Ultrasound-sensitizing nanoparticle complex for overcoming the blood-brain barrier: an effective drug delivery system.
International journal of nanomedicine · 2019-01 · Ha SW, Hwang K, Jin J 외 5
- An ultrasound-responsive dual-modal US/T1 -MRI contrast agent for potential diagnosis of prostate cancer.
Journal of magnetic resonance imaging : JMRI · 2018-12 · Yoon YI, Ha SW, Lee HJ
Patents
KIPRIS · applicant-matchedPCT · Published · 2026-01 · Application PCT/KR2026/001225
PCT · Published · 2025-11 · Application PCT/KR2025/019007
PCT · Published · 2025-11 · Application PCT/KR2025/019008
PCT · Published · 2025-11 · Application PCT/KR2025/019005
PCT · Published · 2025-11 · Application PCT/KR2025/019004
Published · 2025-03 · Application 1020250040343
Published · 2025-02 · Application 1020250013635
Published · 2025-01 · Application 1020250010527
Published · 2025-01 · Application 1020250005502
Published · 2025-01 · Application 1020250005504
Show 96 more patents
Published · 2025-01 · Application 1020250005503
Published · 2025-01 · Application 1020250000369
Published · 2024-12 · Application 1020240191910
Published · 2024-11 · Application 1020240157430
Published · 2024-10 · Application 1020240141322
PCT · Published · 2024-08 · Application PCT/KR2024/011836
PCT · Published · 2024-08 · Application PCT/KR2024/011833
Rejected · 2024-08 · Application 1020240105671
Rejected · 2024-08 · Application 1020240105733
US · Registered · 2024-08 · Application 18793474
PCT · Published · 2024-08 · Application PCT/KR2024/011313
Published · 2024-07 · Application 1020240101947
US · Published · 2024-06 · Application 18745707
EP · Published · 2023-11 · Application 23959558.0
PCT · Published · 2023-11 · Application PCT/KR2023/019290
Registered · 2023-11 · Application 1020230165313
EP · Published · 2023-11 · Application 23959538.2
PCT · Published · 2023-11 · Application PCT/KR2023/018947
Registered · 2023-11 · Application 1020230163682
PCT · Published · 2023-10 · Application PCT/KR2023/016606
EP · Published · 2023-08 · Application 23191565.3
US · Published · 2023-08 · Application 18448431
US · Published · 2023-07 · Application 18362164
US · Published · 2023-07 · Application 18358371
US · Registered · 2023-07 · Application 18358359
PCT · Published · 2023-07 · Application PCT/KR2023/010440
EP · Registered · 2023-07 · Application 23186537.9
EP · Registered · 2023-07 · Application 23186554.4
Rejected · 2023-07 · Application 1020230090886
PCT · Published · 2023-04 · Application PCT/KR2023/005790
Rejected · 2023-04 · Application 1020230054041
Registered · 2023-04 · Application 1020230050107
PCT · Published · 2023-02 · Application PCT/KR2023/002627
Registered · 2023-01 · Application 1020230011192
PCT · Published · 2022-12 · Application PCT/KR2022/019444
PCT · Published · 2022-12 · Application PCT/KR2022/019445
US · Published · 2022-12 · Application 18261830
US · Registered · 2022-12 · Application 18262632
EP · Registered · 2022-12 · Application 22904569.5
EP · Registered · 2022-12 · Application 22904570.3
PCT · Published · 2022-08 · Application PCT/KR2022/012533
Rejected · 2022-07 · Application 1020220091126
Abandoned · 2022-02 · Application 1020220025432
PCT · Published · 2022-02 · Application PCT/KR2022/001847
US · Published · 2022-02 · Application 18264628
EP · Published · 2022-02 · Application 22750078.2
Registered · 2022-02 · Application 1020220015104
Registered · 2021-12 · Application 1020210175189
Registered · 2021-12 · Application 1020210175227
Registered · 2021-12 · Application 1020210175190
CN · Published · 2021-11 · Application 202180081965.6
PCT · Published · 2021-11 · Application PCT/KR2021/017744
US · Published · 2021-11 · Application 18256143
EP · Published · 2021-11 · Application 21903710.8
Rejected · 2021-08 · Application 1020210115791
Rejected · 2021-08 · Application 1020210113377
EP · Registered · 2021-08 · Application 21189428.2
PCT · Published · 2021-05 · Application PCT/KR2021/005634
US · Registered · 2021-05 · Application 17923510
EP · Published · 2021-05 · Application 21799940.8
Registered · 2021-04 · Application 1020210044785
PCT · Published · 2021-04 · Application PCT/KR2021/004131
US · Published · 2021-04 · Application 17997384
EP · Published · 2021-04 · Application 21795405.6
Registered · 2021-04 · Application 1020210042529
US · Registered · 2021-02 · Application 18269733
EP · Registered · 2021-02 · Application 21917815.9
PCT · Published · 2021-02 · Application PCT/KR2021/002282
US · Registered · 2021-02 · Application 17171060
Registered · 2021-01 · Application 1020210000782
Registered · 2020-12 · Application 1020200188849
Registered · 2020-12 · Application 1020200169867
Registered · 2020-11 · Application 1020200144041
Registered · 2020-09 · Application 1020200122036
PCT · Published · 2020-09 · Application PCT/KR2020/011712
US · Published · 2020-09 · Application 17753373
EP · Published · 2020-09 · Application 20860485.0
Registered · 2019-12 · Application 1020190173640
Registered · 2019-09 · Application 1020190108278
PCT · Published · 2019-02 · Application PCT/KR2019/001523
Registered · 2018-02 · Application 1020180015930
CN · Published · 2017-09 · Application 201780059649.2
Registered · 2017-09 · Application 1020170125169
US · Registered · 2017-09 · Application 16337319
EP · Published · 2017-09 · Application 17856751.7
PCT · Published · 2017-09 · Application PCT/KR2017/010744
Rejected · 2016-12 · Application 1020160171538
PCT · Published · 2015-10 · Application PCT/KR2015/011580
Rejected · 2014-10 · Application 1020140149641
CN · Published · 2014-10 · Application 201480077306.5
US · Registered · 2014-10 · Application 15126472
EP · Registered · 2014-10 · Application 14886311.1
Expired · 2014-03 · Application 1020140032057
PCT · Published · 2013-08 · Application PCT/KR2013/006993
Registered · 2013-08 · Application 1020130092029
Rejected · 2010-04 · Application 1020100039720
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive1
- OpenAIOAI-SearchBot68
- GoogleGoogleOther3
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
- MicrosoftBingbot1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for IMGT Corporation Limited and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsMedical Devices
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Founded in 2001 and KOSDAQ-listed in 2022, Bistos manufactures fetal, neonatal, and patient monitoring medical devices.
KOSDAQ-listed aesthetic medical device company producing PICO, DUAL HI, and other anti-aging and body-contouring devices.
CLASSYS Inc., established in 2015 and listed on KOSDAQ, makes aesthetic medical devices using HIFU, MRF, MNRF, and laser technologies.
KOSDAQ-listed lab equipment company manufacturing and distributing ultra-low temperature freezers, centrifuges, and autoclaves.
KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.
KOSDAQ-listed medical device company producing HIFU devices DOUBLO/V-RO and the Synerjet non-invasive drug delivery system for aesthetic dermatology.
MITECH CO.,LTD., founded in 1991 and listed on KOSDAQ in 2018, makes non-vascular stents and distributes Fujifilm endoscopy equipment.
Founded in 2019 and KOSDAQ-listed the same year, WON TECH makes aesthetic laser, RF, and HIFU devices including Oligio and Picocare.
Interojo, founded 2000 and KOSDAQ-listed 2010, manufactures contact lenses under its Clalen brand domestically and via OEM/ODM overseas.
Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.
Founded in 2000 and KOSDAQ-listed in 2013, Corentec makes artificial joints; hip and knee implants exceed 85% of revenue.
Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition